1. Neurology

Category Archives: Neurology

Parkinson’s disease expert Dr. Lisa Shulman on her research into Parkinson’s disease – Video

Posted on by


Parkinson #39;s disease expert Dr. Lisa Shulman on her research into Parkinson #39;s disease
Lisa Shulman, M.D., Fellow of the American Academy of Neurology (AAN), of the University of Maryland, is interviewed by Mike Smolinsky, managing editor of Ne...

By: Neurology Now Magazine

Excerpt from:
Parkinson's disease expert Dr. Lisa Shulman on her research into Parkinson's disease - Video

Are Pregnant Women with Epilepsy Properly Counseled on Risks for Malformations? – Video

Posted on by


Are Pregnant Women with Epilepsy Properly Counseled on Risks for Malformations?
Are neurologists discussing folic acid supplementation and contraception with women of childbearing age? A 2013 AAN annual meeting report found that in nearl...

By: Neurology Today

Read more from the original source:
Are Pregnant Women with Epilepsy Properly Counseled on Risks for Malformations? - Video

‘Neurology in Crisis’: Drs. Orly Avitzur and Neil Busis Discuss Practice Changes – Video

Posted on by


#39;Neurology in Crisis #39;: Drs. Orly Avitzur and Neil Busis Discuss Practice Changes
What should neurologists do to mitigate changes in practice? Neurology Today Associate Editor Orly Avitzur, MD, a neurologist in private practice in Tarrytow...

By: Neurology Today

Original post:
'Neurology in Crisis': Drs. Orly Avitzur and Neil Busis Discuss Practice Changes - Video

New Diagnostic Blood Assay and a Novel Treatment for Inclusion Body Myositis – Video

Posted on by


New Diagnostic Blood Assay and a Novel Treatment for Inclusion Body Myositis
Two new developments reported at the 2013 American Neurological Association annual meeting have neuromuscular specialists excited for the first time in a whi...

By: Neurology Today

Read the original:
New Diagnostic Blood Assay and a Novel Treatment for Inclusion Body Myositis - Video

Should neurologists be lowering blood pressure acutely in intracranial hemorrhage? – Video

Posted on by


Should neurologists be lowering blood pressure acutely in intracranial hemorrhage?
Rapid, intensive lowering of intracerebral blood pressure (BP) did not appear to reduce death or severe disability in patients with intracerebral hemorrhage,...

By: Neurology Today

Read more here:
Should neurologists be lowering blood pressure acutely in intracranial hemorrhage? - Video

How can neurologists incorporate shared decision-making with their patients? – Video

Posted on by


How can neurologists incorporate shared decision-making with their patients?
A survey, reported in JAMA Internal Medicine, reported that primary care physicians are not consistently consulting with patients in discussions and decision...

By: Neurology Today

Read the original post:
How can neurologists incorporate shared decision-making with their patients? - Video

ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo? – Video

Posted on by


ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo?
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo?

By: Mark Saracino, Board Certified Chiropractic Neurologist

Go here to read the rest:
ABC News Nightline Video: Chiropractic Neurology: Breakthrough Treatment or Placebo? - Video

China approves seaweed-based Alzheimer’s drug. It’s the first new one in 17 years – WAPT Jackson

Posted on by

Related video above: Researchers Developing Most Powerful MRI Hope to Help Detect Illnesses Like Alzheimers Disease SoonerAuthorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai-based pharmaceutical company that will be bringing the new drug to market.Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley."These results advance our understanding of the mechanisms that play a role in Alzheimer's disease and imply that the gut microbiome is a valid target for the development of therapies," neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.Alzheimer's disease, which starts with memory loss and escalates to severe brain damage, is believed to cause 60% to 70% of the cases of dementia reported worldwide, according to the World Health Organization. Dementia affects an estimated 50 million people worldwide, including 9.5 million people in mainland China, Hong Kong and Taiwan.Named after Alois Alzheimer, the neuropathologist who discovered the disease in 1906, it has so far confounded researchers and pharmaceutical companies.In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.

Related video above: Researchers Developing Most Powerful MRI Hope to Help Detect Illnesses Like Alzheimers Disease Sooner

Authorities in China have approved a drug for the treatment of Alzheimer's disease, the first new medicine with the potential to treat the cognitive disorder in 17 years.

The seaweed-based drug, called Oligomannate, can be used for the treatment of mild to moderate Alzheimer's, according to a statement from China's drug safety agency. The approval is conditional however, meaning that while it can go on sale during additional clinical trials, it will be strictly monitored and could be withdrawn should any safety issues arise.

In September, the team behind the new drug, led by Geng Meiyu at the Shanghai Institute of Materia Medica under the Chinese Academy of Sciences, said they were inspired to look into seaweed due to the relatively low incidence of Alzheimer's among people who consume it regularly.

In a paper in the journal Cell Research, Geng's team described how a sugar contained within seaweed suppresses certain bacteria contained in the gut which can cause neural degeneration and inflammation of the brain, leading to Alzheimer's.

This mechanism was confirmed during a clinical trial carried out by Green Valley, a Shanghai-based pharmaceutical company that will be bringing the new drug to market.

Conducted on 818 patients, the trial found that Oligomannate -- which is derived from brown algae -- can statistically improve cognitive function among people with Alzheimer's in as little as four weeks, according to a statement from Green Valley.

"These results advance our understanding of the mechanisms that play a role in Alzheimer's disease and imply that the gut microbiome is a valid target for the development of therapies," neurologist Philip Scheltens, who advises Green Valley and heads the Alzheimer Center Amsterdam, said in the statement.

The company said Oligomannate will be available in China "very soon," and it is currently seeking approval to market it abroad, with plans to launch third-phase clinical trials in the US and Europe in early 2020.

Alzheimer's disease, which starts with memory loss and escalates to severe brain damage, is believed to cause 60% to 70% of the cases of dementia reported worldwide, according to the World Health Organization. Dementia affects an estimated 50 million people worldwide, including 9.5 million people in mainland China, Hong Kong and Taiwan.

Named after Alois Alzheimer, the neuropathologist who discovered the disease in 1906, it has so far confounded researchers and pharmaceutical companies.

In October, US pharmaceutical giant Biogen said it would pursue Food and Drug Administration (FDA) approval for an experimental treatment called aducanumab, after announcing in March it was canceling a large clinical trial for the drug.

Johnson & Johnson, Merck, Pfizer and Eli Lilly have all previously abandoned projects to develop a drug for Alzheimer's after unsatisfactory clinical data.

More:
China approves seaweed-based Alzheimer's drug. It's the first new one in 17 years - WAPT Jackson

How did a neuroscientist ameliorate seizures in her daughter’s Lennox-Gastaut syndrome? – Video

Posted on by


How did a neuroscientist ameliorate seizures in her daughter #39;s Lennox-Gastaut syndrome?
In this video segment, Neurology Today #39;s Editor-in-Chief Steven P. Ringel, MD, talks with Tracy Dixon-Salazar, PhD, associate research director at Citizens U...

By: Neurology Today

Go here to read the rest:
How did a neuroscientist ameliorate seizures in her daughter's Lennox-Gastaut syndrome? - Video


  1. Neurology